Description

Efavirenz-13C6 is the 13C-labeled Efavirenz. Efavirenz (DMP 266) is a potent inhibitor of the wild-type HIV-1 reverse transcriptase with a Ki of 2.93 nM and exhibits an IC95 of 1.5 nM for the inhibition of HIV-1 replicative spread in cell culture[1].–Applications–Formula-C8 13C6H5D4ClF3NO2-Citation–References-[1]Held DM, et al. Differential susceptibility of HIV-1 reverse transcriptase to inhibition by RNA aptamers in enzymatic reactions monitoring specific steps during genome replication. J Biol Chem. 2006 Sep 1;281(35):25712-22.|[2]Grobler JA, et al. HIV-1 reverse transcriptase plus-strand initiation exhibits preferential sensitivity to non-nucleoside reverse transcriptase inhibitors in vitro. J Biol Chem. 2007 Mar 16;282(11):8005-10.|[3]Young SD, et al. L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother. 1995 Dec;39(12):2602-5.|[4]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. -CASNumber-1261394-62-0-MolecularWeight-325.66-Compound Purity–SMILES-[2H]C1([2H])C([2H])([2H])C1C#C[C@]2([13C]3=[13CH][13C](Cl)=[13CH][13CH]=[13C]3NC(O2)=O)C(F)(F)F-Research_Area-Infection; Cancer-Solubility-10 mM in DMSO-Target-Autophagy;Endogenous Metabolite;HIV;Isotope-Labeled Compounds;Reverse Transcriptase-Isoform-HIV-1-Pathway-Anti-infection;Autophagy;Metabolic Enzyme/Protease;Others-MCE Product type-Isotope-Labeled Compounds